By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Cardiovascular disease is the main cause of death and morbidity worldwide. Several subtypes of cardiovascular disease need novel surgical and interventional diagnostic and therapeutic approaches, as well as devices made of highly sophisticated biomaterials.
The recognition and understanding of these devices’ complications, many of which are related to the biomaterials that comprise them, has resulted in iterative efforts to improve their performance and safety through biomaterials and device research and development, which has translated into better patient care.
Cardiovascular medical devices such as prosthetic heart valves, coronary stents, endovascular grafts, and angioplasty balloon catheters save countless lives each year and significantly enhance the quality of life for millions of people. However, the design, development, and production of modern implanted cardiovascular devices is a difficult, time-consuming, and capital-intensive process for device makers.
Furthermore, because of the higher level of danger they represent to patients, cardiovascular devices are subject to extensive assessment and control by medical device authorities in the majority of large nations.
In the EU, for example, implanted cardiovascular devices will soon be expected to fulfill the more strict standards of the new EU medical device regulation (MDR).Overcoming these and other obstacles requires both in-depth technical expertise and significant regulatory experience for producers of cardiovascular devices.
These hurdles can be especially onerous for small and medium-sized businesses, which account for the vast majority of medical device makers. Cardiovascular medical devices, including the underlying pathophysiology of the disorders for which they are designed and utilized to treat, pertinent biomaterials from which they are made, and the most serious problems that must be avoided, minimized, or controlled.
It focuses on biomaterials and engineering design issues relevant to cardiac valve prostheses, pacemakers and implantable cardioverter-defibrillators, implantable cardiac assist devices and artificial hearts, and miscellaneous intracardiac devices, such as septal defect closure devices and left atrial occlusion devices, to treat cardiovascular disease in a minimally invasive manner.
The Egypt Cardiovascular Medical Devices Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The difficulties that patients with cardiovascular disease face, including physical and mental burdens, have fueled the desire to reduce risk factors and halt disease development. The discovery of connections between cardiovascular, renal, and metabolic illnesses (CVRM) lies at the heart of the approach to holistic therapy for CVRM patients.
While secondary prevention is important in the treatment of patients with cardiovascular disease, the goal is to go a step further and treat the patient as a whole. Every day, people with coronary artery disease, including those who have already had a heart attack, are being helped to avoid life-threatening cardiovascular events. However, there is an urgent need for novel and comprehensive ways to help minimize CV morbidity.
The Egyptian EDA is the single body in charge of drug control, registration, trading, and supervision, as well as licensing pharmaceutical and medical device firms and regulating drug and device registration and pricing processes, among other things. All medical items manufactured, imported, and sold in Egypt must be EDA-registered. Nonetheless, Egypt has stronger limitations on importing medical items, and the registration procedure might be lengthy.
At the beginning of this year, LEPU SURGICAL’s PROCISION 1000 Ultrasonic Surgical System received EU CE certification as well as Brazilian ANVISA registration. Since its introduction, the PROCISION 1000 Ultrasonic Surgical System has been sold to nations and regions including Europe, South America, Southeast Asia, India, and the Middle East. There are several types of scalpels in the ultrasonic scalpel system product range.
Medtronic ICDs provide a healthcare practitioner extra reasons to pick an ICD since they have benefits in certain areas of therapy such as technology and algorithms that prevent inappropriate and unneeded shocks. Exclusive algorithms for managing atrial fibrillation (AF) in ICD patients. The platform’s unique algorithms assist health care professionals in achieving the best potential outcomes.
